Avapritinib Therapy in Advanced Gastrointestinal Stromal Tumor with PDGFRA Mutation

As the PDGFRA gene D842V mutation doesn’t respond to targeted therapy, the previous primary treatment for patients with recurrent metastatic tumors with this mutation was active surgery. The advent of Avapritinib provided more treatment options for such patients. Targeted therapy can improve patient prognosis and create conditions for radical surgery. Therefore, in the future targeted therapy combined with surgery will play an extremely important role in the diagnosis and treatment of GISTs with primary drug resistance, for example, D842V.